We and others have shown that Syk is required for the development of autoantibody-induced arthritis in experimental mice (24, 33–35) and Syk has been proposed as a therapeutic target in human rheumatoid arthritis (61–63). The gene discussed is SYK; the disease is arthritic joint disease.